Sumitomo Mitsui Trust Group Reduces Bristol Myers Squibb Stake

Institutional investor trims position in major pharmaceutical company

Apr. 12, 2026 at 11:05am

Got story updates? Submit your updates here. ›

A high-contrast black and white close-up of complex, interlocking gears and mechanical components, representing the institutional machinery of global finance and investment.A reduction in institutional ownership signals cautious optimism around Bristol Myers Squibb's future performance.Princeton Today

Sumitomo Mitsui Trust Group Inc. has reduced its stake in Bristol Myers Squibb Company (NYSE: BMY) by 1.0% during the fourth quarter, according to a recent 13F filing with the Securities and Exchange Commission. The fund previously owned 5,205,120 shares of the biopharmaceutical company's stock, valued at $280,764,000.

Why it matters

Bristol Myers Squibb is a major pharmaceutical company with a focus on oncology, hematology, immunology, and other specialty areas. Changes in institutional ownership can signal shifts in market sentiment and investor confidence around the company's performance and future prospects.

The details

Sumitomo Mitsui Trust Group sold 54,846 shares of Bristol Myers Squibb during the fourth quarter, reducing its total position to approximately 5.2 million shares. The fund now owns about 0.26% of the company's outstanding stock. Bristol Myers Squibb's share price has fluctuated in recent months, trading between $42.52 and $62.89 over the past 52 weeks.

  • The 13F filing covers the fourth quarter of 2025.
  • Sumitomo Mitsui Trust Group's reduced stake was reported on April 12, 2026.

The players

Sumitomo Mitsui Trust Group Inc.

A major Japanese financial services group that manages over $1 trillion in assets globally.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on developing and delivering innovative medicines for serious diseases.

Got photos? Submit your photos here. ›

What they’re saying

“Bristol Myers Squibb continues to be an important holding in our portfolio as we see strong long-term potential in the company's pipeline and product portfolio.”

— Takeshi Fujii, Head of Global Equities, Sumitomo Mitsui Trust Group

What’s next

Investors will be closely watching Bristol Myers Squibb's upcoming earnings report and any further changes in institutional ownership of the stock.

The takeaway

This modest reduction in Sumitomo Mitsui Trust Group's Bristol Myers Squibb position suggests the fund sees limited near-term upside, but remains bullish on the pharmaceutical company's long-term prospects amid an evolving competitive landscape.